{"id":"W4403977769","doi":"10.1007/s11523-024-01102-8","title":"Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Olaparib; Maximum tolerated dose; Open label; Refractory (planetary science); Oncology; Solid tumor; Internal medicine; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001192162,0.001407957,0.002082554,0.0004311732,0.0004215504,0.001302325,0.0008467949,0.001208111,0.003109382],"category_scores_gemma":[0.0007476656,0.0005472257,0.001314941,0.0005203362,0.0008999436,0.001058017,0.000354398,0.00320278,0.0008201802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008900537,"about_ca_system_score_gemma":0.001405193,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005591455,"about_ca_topic_score_gemma":0.001427198,"domain_scores_codex":[0.9996663,0.0001341026,0.00002301446,0.00006718856,0.0000363659,0.00007299596],"domain_scores_gemma":[0.9993001,0.0001304116,0.0001092789,0.00005084685,0.00003494303,0.0003744552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8169699,0.04396749,0.0047403,0.0009252232,0.001157161,0.000307513,0.0002691955,0.002643741,0.02350623,0.0002355334,0.003839758,0.1014379],"study_design_scores_gemma":[0.8155403,0.1739563,0.005356362,0.0000377924,0.0002302846,0.0002670546,0.00003850847,0.001292368,0.001346966,0.0002028924,0.001706762,0.00002445153],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923689,0.002704868,0.0003230239,0.0004404456,0.0001299763,0.00138252,0.0007665547,0.00009731662,0.001786323],"genre_scores_gemma":[0.9915497,0.001811714,0.00103807,0.0008978263,0.0002332619,0.001286778,0.001718158,0.00002451422,0.001439986],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003109382,"threshold_uncertainty_score":0.01040196,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04736721586451495,"score_gpt":0.3932493215087382,"score_spread":0.3458821056442233,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}